TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02984384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Molecular Weight Heparin (LMWH)
Description: The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.
Study: NCT01554566

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: honey
Description: The subjects in the I/C group consumed 0.5 ml honey/kg/day in the first 12-week period (period 1) while the subjects in the C/I group did not receive honey as a control in period 1. After period 1 the subjects of each group exchanged their protocol for the following 12-week period (period 2).
Study: NCT03523546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer Episode Payment Model (CEM)
Description: Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.
Study: NCT00911508

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial ablation
Description: St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path~Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF~Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System~Bard: Stinger~Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate or Rhythm Control Therapy
Description: Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg~Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg
Study: NCT04076280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sodium Watcher Program-Hypertension
Description: The Sodium Watcher Program -Hypertension intervention consists of 14 weeks of education \[4 weekly education sessions (45 minutes)followed by 5 bi-weekly sessions 5-20 minutes\] that will be held at the dyads' preferred time delivered to their homes using a video conferencing program through an iPad.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the usual care group receive their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium restricted diet and take medications as ordered. Usual care consists of recommendations to follow a sodium restricted diet, but without explicit skills training including instructions on gradual adaptation to sodium restricted diet, follow-up of progress or provision of monitoring.
Study: NCT01345162

Intervention type: DRUG
Group type: OTHER
Intervention: Ketorolac postoperative
Description: Ketorolac 10mg 1cp x 3/die

Intervention type: DRUG
Group type: OTHER
Intervention: postoperative Patrol
Description: acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die

Intervention type: DRUG
Group type: OTHER
Intervention: intraoperative analgesia
Description: ketorolac 30 mg iv

Intervention type: DRUG
Group type: OTHER
Intervention: intraoperative analgesia
Description: ketorolac 30 mg iv

Intervention type: DRUG
Group type: OTHER
Intervention: intraoperative analgesia
Description: Tramadol 100 mg if Weight over 50 kg, 50 mg if weight below 50 kg

Intervention type: DRUG
Group type: OTHER
Intervention: intraoperative analgesia
Description: Tramadol 100 mg if Weight over 50 kg, 50 mg if weight below 50 kg
Study: NCT04631835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10352
Description: Participants will receive single dose of HS-10352 on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Study: NCT03198559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram, (National Drug Code) NDC 0378-4141-01
Description: This study will provide open label disulfiram. Participants will take 2 grams (4x500mg tablets) of disulfiram per day for a total of 28 days
Study: NCT01530971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental 3LPM oxygen via canula
Description: Parturients will receive supplemental oxygen (3LPM) via nasal canula
Study: NCT01811095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Training with the da Vinci® Skills Simulator to complete a proficiency-based curriculum in 6 simulator exercises relevant to robotic suturing over a 5-week period. We will ask participants in the training group to aim to complete the exercises Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2,and Suture sponge 3 to the target score (overall score green checkmark and all component scores to the level of yellow triangle or green checkmark, equivalent to a completed score) on two non-consecutive attempts. For the Suturing skills (SymbionixTM): Horizontal suturing defect task, the scoring is different. For this task, we have elected to ask participants to aim to complete the task ten times,rather than to achieve a certain target score.
Study: NCT03198559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat, NDC 00006-0568-40
Description: This study will provide open label vorinostat. Participants will take 400mg (4x100mg capsules) of vorinostat per day on days 8, 9, 10 and days 22, 23, 24.
Study: NCT00749983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose supplementation
Study: NCT04139928

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Picometer-ionic form of magnesium chloride
Description: Single-dose (300 mg) of the picometer-ionic form of magnesium chloride
Study: NCT00633997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: 50 mg orally twice daily for 10 days (last dose morning of day 10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study: NCT01354405

Intervention type: DRUG
Intervention: Lanreotide
Description: 120 mg every 28 days intramuscular
Study: NCT02456740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by subcutaneous injection once a month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by subcutaneous injection once a month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once a month
Study: NCT00878904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Study: NCT02905058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: oral non-steroidal antiinflammatory drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04456140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Watch pre-test genetic counseling video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo genetic testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT00995124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeutraLice Lotion
Description: Head lice topical application to be applied once for 10 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeutraLice Advance Solution
Description: head lice application to be applied once for 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moov Head Lice Solution
Description: Single application for head lice with 10 min application time.
Study: NCT02969044

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 200mg pill every day (QD) for 8 weeks
Study: NCT00961857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin phosphate (+) metformin hydrochloride
Description: place holder - do not post

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin 500 mg
Description: A single dose of metformin 500 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: sitagliptin
Description: A single 50 mg tablet of sitagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: sitagliptin
Description: A single 50 mg tablet of sitagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
Description: A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
Description: A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin 1000 mg
Description: A single dose of metformin 1000 mg tablets
Study: NCT03884361

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal Microbiome as result of aminocentesis
Description: we will take a blood samples and a vaginale samples after and before the aminicentesis and check if the sample that we took after is different and contain microrganisms , if we find a different o we can say that as result of the Elective Amniocentesis
Study: NCT00878904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT01027325

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: Starch digestibility and carbohydrate quantity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Starch digestibility and carbohydrate quantity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Starch digestibility and carbohydrate quantity
Study: NCT03775512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Ablation with QDOT Micro
Description: Subjects will be ablated using QDOT Micro catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Ablation with QDOT Micro
Description: Subjects will be ablated using QDOT Micro catheter
Study: NCT00724243

Intervention type: DRUG
Intervention: Infliximab
Description: Infliximab given in accordance with the local summary of product characteristics
Study: NCT01938443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256098
Description: GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256098
Description: GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.
Study: NCT01444638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound examination
Description: Trainees will receive pre-procedure U/S guided examination of the parturient's back.
Study: NCT02554409

Intervention type: BIOLOGICAL
Intervention: Quadrivalent Intradermal Influenza Vaccine (QIV)
Description: No Intervention as part of this protocol
Study: NCT01349881

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eflornithine placebo & sulindac placebo
Description: Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eflornithine & sulindac placebo
Description: Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine placebo & sulindac
Description: Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine plus sulindac
Description: Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
Study: NCT01156636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50 mg 3 times/day for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04235127

Intervention type: OTHER
Intervention: sociodemographic variables, somatic conditions, mental disorders, treatment and drug use
Description: * sociodemographic variables~* history of self-injurious behaviours; all types of somatic conditions; neurodevelopmental, mental, behavioural, personality and substance use disorders; all types of medical procedures performed; and number and type of healthcare contacts.~* prescriptions for psychopharmacological products~* the Suicidal Scale of the Mini-International Neuropsychiatric Interview, the type and lethality of the attempt that warranted evaluation, presence and type of mental disorder, hopelessness, impulsivity, aggressiveness, altered state of conscience, use or dependence of alcohol, use or dependence of illicit drugs, serious somatic disease (including chronic diseases, chronic pain, and disabilities), living status, presence of family or social support, social problems, stressful life events, access to lethal means, and family history of suicide
Study: NCT00878904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT04039282

Intervention type: DEVICE
Group type: OTHER
Intervention: myfood24
Description: online website for dietary analysis

Intervention type: DEVICE
Group type: OTHER
Intervention: myfood24
Description: online website for dietary analysis
Study: NCT01757821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real 6-Hz primed low-frequency rTMS
Description: 10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham 6-Hz Primed low-frequency rTMS
Description: 10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real 1-Hz rTMS only
Description: 20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region
Study: NCT00244426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indobufen
Description: Indobufen capsules 100 and 200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: Acetylsalicylic acid capsules 300mg
Study: NCT03274934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: face-to-face and online support group:
Description: 5-week intervention according to Acceptance and Commitment Therapy principles with the web-and mobile-based Youth COMPASS program, face-to-face support (2 meetings) and weekly online mobile support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: only online support group:
Description: 5-week intervention according to ACT principles with the web-and mobile-based Youth COMPASS program, no face-to-face support, weekly mobile online support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group, no intervention, school counseling as usual. (one third of the participants is randomly assigned to this group)
Study: NCT03436212

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitoring (CGM)
Description: DEXCOMG4 device
Study: NCT02819882

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT04057430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GumChucks
Description: GumChucks® is an innovative flossing system resembling mini nunchucks. The two-handle design eliminates the need to wrap the floss around fingers, and a proper flossing technique is facilitated by the nature of its curved shaped.
Study: NCT02819882

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT05038397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theraspere
Description: Prior to the administration of TheraSphere, the patient should undergo hepatic arterial catheterization using balloon catheterization or other appropriate angiographic techniques to prevent extrahepatic shunting. Following the placement of the hepatic catheter, 75 MBq to 150 MBq (2 mCi to 4 mCi) of Tc-99m MAA is administered into the hepatic artery to determine the extent of A-V shunting to the lungs and to confirm the absence of gastric and duodenal flow. When the possibility of extrahepatic shunting has been evaluated and the patient deemed acceptable for treatment, TheraSphere may be administered.
Study: NCT04534868

Intervention type: OTHER
Group type: OTHER
Intervention: taking macroscopic and dermoscopic pictures of suspicious skin lesions
Description: If there is any diagnostic doubt about a skin lesion, teledermoscopy will be used, if the patient agrees.~* A table containing the useful information about the patient for the lesion's analysis will be completed.~* The pictures will be taken with a Fotofinder Handyscope. The photos will be integrated into the patient's electronic medical record (CareConnect program).~* The photo is anonymized via a serial number assigned by the Handyscope application.~* Sending photos and information via a secure email address to the dermatologists.~* Response from the dermatologist (Prof. Tromme or Dr Harkemanne) in the following days also via email.~* Contact (consultation or telephone call depending on the diagnosis) with the patient to communicate the results and the procedure to be followed.~* This information (emails containing the dermatological report) will be saved in the patient's computerized medical file (CareConnect program) then deleted from the mailbox
Study: NCT00993590

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: M CHESS
Description: Smartphone with access to MCHESS, an asthma control system that provides easy-to-access, just-in-time information and support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M CHESS
Description: Smartphone with access to MCHESS, an asthma control system that provides easy-to-access, just-in-time information and support.
Study: NCT01524120

Intervention type: DEVICE
Intervention: Endoscopy (EPK-i, Pentax, Tokyo, Japan)
Description: Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
Study: NCT04474717

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breath Condensate Collection
Description: Breath Condensate Collection

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: clinical examination, spirometry
Description: spirometry

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood monocyte assay
Description: study of blood monocytes in the laboratory of cell technology
Study: NCT03684902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: emergency midline exploratory laparotomy
Description: Once an adequate level of anesthesia has been reached, the initial incision into the skin may be made. A scalpel is first used to cut into the superficial layers of the skin.with the diathermy The incision is then continued through the subcutaneous fat, the abdominal muscles, and finally, the peritoneum. (Morris J ;2017) For all the patients, closure of midline laparotomy wound was en-mass closure done with non-absorbable No. 1 (Polypropylene) or slowly absorbable (PDS) (double loop). sutures in continuous single layer fashion with 1 cm interval. (Morris J ;2017) The operative details were recorded with special consideration to the operative diagnosis, presence and types of adhesions, duration of surgery, the need for diversion and stoma formation, the use of intraperitoneal drain and the suture material to close the rectus sheath.
Study: NCT04057430

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: String floss
Description: Traditional string floss used in this study was Oral-B Glide® Pro-Health Original Floss
Study: NCT04364295

Intervention type: DEVICE
Intervention: Spinal Surgery with SeaSpine product
Description: Implanted with SeaSpine spinal or orthobiologic product
Study: NCT04373720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo standard of care MRI
Study: NCT03226496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Study: NCT00244101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PS Group
Description: Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.